Researchers at Nagoya University in Japan have hatched the first-ever bird from an artificial eggshell, made from a glass cup internally coated with a layer of fluoride resin.
The success of this technology paves the way for the mass production of useful substances such as insulin and other hormones in genetically-engineered chicken eggs. Previous genetic engineering of a bird required the original eggshell to be cracked to enable the introduction of the foreign gene, followed by artificial incubation via transplantation into another eggshell. This procedure has a death rate of almost 40%.
The new method transfers the genetically-engineered embryo to the man-made container complete with a layer of crushed eggshell. After 18 days of incubation, the chick will hatch. The success rate to date is only 12%, but it is thought that, with thorough investigations into the optimal conditions required for hatching, and if the difficulties of compatibility between the chick and the eggshell can be resolved, researchers would be able to reach the 90% hatch rate seen in natural conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze